- Home
- TNXP vs SIF Comparison
TNXP vs SIF Comparison
Compare TNXP & SIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- SIF
- Stock Information
- Founded
- TNXP 2007
- SIF 1913
- Country
- TNXP United States
- SIF United States
- Employees
- TNXP N/A
- SIF N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- SIF Office Equipment/Supplies/Services
- Sector
- TNXP Health Care
- SIF Industrials
- Exchange
- TNXP Nasdaq
- SIF Nasdaq
- Market Cap
- TNXP 19.5M
- SIF 21.7M
- IPO Year
- TNXP N/A
- SIF N/A
- Fundamental
- Price
- TNXP $0.20
- SIF $3.88
- Analyst Decision
- TNXP Strong Buy
- SIF
- Analyst Count
- TNXP 2
- SIF 0
- Target Price
- TNXP $53.50
- SIF N/A
- AVG Volume (30 Days)
- TNXP 51.5M
- SIF 18.7K
- Earning Date
- TNXP 11-12-2024
- SIF 12-27-2024
- Dividend Yield
- TNXP N/A
- SIF N/A
- EPS Growth
- TNXP N/A
- SIF N/A
- EPS
- TNXP N/A
- SIF N/A
- Revenue
- TNXP $11,291,000.00
- SIF $101,482,000.00
- Revenue This Year
- TNXP $62.53
- SIF N/A
- Revenue Next Year
- TNXP $26.17
- SIF N/A
- P/E Ratio
- TNXP N/A
- SIF N/A
- Revenue Growth
- TNXP 183.05
- SIF 25.24
- 52 Week Low
- TNXP $0.12
- SIF $2.87
- 52 Week High
- TNXP $22.08
- SIF $5.96
- Technical
- Relative Strength Index (RSI)
- TNXP 66.43
- SIF 53.59
- Support Level
- TNXP $0.17
- SIF $3.50
- Resistance Level
- TNXP $0.28
- SIF $3.68
- Average True Range (ATR)
- TNXP 0.02
- SIF 0.18
- MACD
- TNXP 0.01
- SIF 0.05
- Stochastic Oscillator
- TNXP 44.53
- SIF 62.16
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About SIF SIFCO Industries Inc.
SIFCO Industries Inc is engaged in the production of forgings and machined components for the Aerospace and Energy, Defense and Commercial Space markets. Its processes and services include forging, heat-treating and machining. It serves original equipment manufacturers (OEM) as well as aftermarket customers. Its products are made of steel, stainless steel, titanium and aluminium and include OEM and aftermarket components for aircraft and industrial gas turbine engines, steam turbine blades, structural airframe components, aircraft landing gear components, aircraft wheels and brakes, critical rotating components for helicopters and industrial products. Substantial revenue is derived from North America as well as operates in Europe.